GE Healthcare launched Scintillation Proximity Assay (SPA) GPCR Assays offering pre-developed assay conditions for G-protein-coupled receptor-ligand binding studies. GE Healthcare said the pre-validated protocols are for speeding up the work of researchers using GPCR receptor membranes in high-throughput screening environments. The protocols can shave as many as 15 days from the GPCR assay development stage, the company added.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.